Influence of sustained-release dexamethasone on intraocular cytokines and growth factors and retinal blood vessels in retinal vein occlusion - Sustained-release dexamethasone induced changes on intraocular cytokines in retinal vein occlusion

niversitätsklinik für Augenheilkunde und Optometrie0 个研究点开始时间: 2013年1月8日最近更新: 2016年8月29日

适应症

试验速览

暂无简介。

•Male or female, at least 18 years of age.
•Ophthalmoscopic evidence of recent BRVO or CRVO (i.e. a history of 3 months or less).
•Macular edema secondary to BRVO or CRVO in the study eye sheduled for intravittreal Ozurdex®.
•Retinal thickness of > 300 µm by OCT in the central subfield of the study eye at baseline.
•VA decrease attributable to the edema.
•Written informed consent has been obtained.
•Female patients of childbearing potential must have a negative urine pregnancy test.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 40
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 40

•Exclusion criteria
•Any of the following will exclude a subject from the study:
•Uncontrolled systemic disease
•Symptoms of a clinically relevant illness in the 3 weeks before the first study day
•Any ocular condition that, in the opinion of the investigator, would prevent a 15-letter improvement in visual acuity (eg severe macular ischemia)
•History of glaucoma, aphakia or presence of anterior chamber intraocular lens, active retinal neovascularization, choroidal neovascularization, significant cataract, presence of rubeosis iridis, any ocular infection, history of pars plana vitrectomy, anticipated need for ocular surgery in the study eye during the study period.
•Contraindication to pupil dilation, known allergy, or contraindication to the use of fluorescein.

发起方

niversitätsklinik für Augenheilkunde und Optometrie